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a b s t r a c t
Mas-related genes (Mrgs) belong to a large family of G protein-coupled receptor genes
found in rodents. HumanMRGXproteins are G protein-coupled 7-transmembrane proteins
sharing 41-52% amino acid identity with each other, but have no orthologs in rodents.
MrgX2 is amember of theMrgX family. MRGX2 is expressed in the small neurons of sensory
ganglia and mast cells. It can interact with a series of factors and genes such as the peptides
substance P, vasoactive intestinal peptide, cortistatin (CST), proadrenomedullin N-terminal
peptide (PAMP), LL-37, PMX-53 and -defensins. MRGX2 is related to nociception, adrenal
gland secretion and mast cell degranulation. Recent research on MrgX2 provides insights
into its role in nociception and anti-microbial activities. This article reviewed the origin,
expression and function of MrgX2, and discussed possible future research focus.
© 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ontents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2. The location, evolution and future research focus of MrgX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.1. The location of MrgX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.2. Rapid evolution of Human MrgX2 (hMrgX2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3. Future research focus of MrgX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3. The expression pattern of MrgX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
4. Interaction of MRGX2 with peptide factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4.1. Substance P and vasoactive intestinal peptide activate MRGX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4.2. Cortistatin (CST), proadrenomedullin N-terminal peptide (PAMP), Dextrorphan and 3-methoxy morphanin
activate MRGX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
4.3. LL-37 activates MRGX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Abbreviations: Mrgs, Mas-related genes; MRG, protein peptides of Mas-related genes; MrgX2, gene of Mas-related G protein-coupled receptor member
2;MRGX2, protein peptides ofMas-related G protein-coupled receptormember X2; DRG, dorsal root ganglion; DRGs, dorsal root ganglia; TRGs, trigeminal
anglia; PCR, polymerase chain reaction; GPCR, G protein-coupled receptor; CST, cortistatin; PAMP, proadrenomedullin N-terminal peptide.
∗ Corresponding author at: Professor, Department of Medicine, Shenzhen University Health Science Centre, Shenzhen, China. Tel.: +86 755 86671916,
ax: +86 755 86671906.
∗∗ Co-Corresponding author at: Professor & Associate Director, Shenzhen University Health Science Centre, Shenzhen, China. Tel: +86 755 86671930,
ax: +86 755 86671906.
E-mail addresses: wqjiang@szu.edu.cn (W. Jiang), shaou@szu.edu.cn (O. Sha).
http://dx.doi.org/10.1016/j.proghi.2015.06.001
079-6336/© 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
12 H. Wu et al. / Progress in Histochemistry and Cytochemistry 50 (2015) 11–17
4.4. PMX-53 may activates human mast cells via MRGX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
4.5. -defensins activate human mast cells via MRGX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
5. The function of MRGX2 and further research clue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
6. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1. Introduction
G protein-coupled receptor (GPCR) genes belong to a family that have been exploited extensively as drug targets. Mas-
related genes (Mrgs) are recently identiﬁed GPCR family genes (Dong et al., 2001, Choi and Lahn, 2003, Vassilatis et al., 2003,
Zhang et al., 2005). TheMrg gene family has 32 murine and 4-7 human genes (hMrgX1-hMrgX7) (Vassilatis et al., 2003).
Interestingly, the mRNAs of Mrgs are expressed predominantly in non-overlapping subsets of non-peptidergic neurons in
the dorsal root ganglia (DRGs) and trigeminal ganglia (TRGs) (Dong et al., 2001, Choi and Lahn, 2003). They are expressed
only in the nociceptive neurons of these sensory ganglia. This speciﬁc expression pattern may imply their signiﬁcant roles
in the physiological and pharmaceutical aspects of pain processing.
System biology, biochemical and immunological studies indicate the amazing complexity of the mechanism of action of
interaction peptides. Mrg genes respond to many biogenic amines and peptides. Agonist binding to these receptors initiates
various G-protein-mediated intracellular reactions such as modulation of adenylate cyclase or Ca2+ mobilization (Okayama
et al., 2008, Siehler et al., 2008, Aicher et al., 2009, Subramanian et al., 2011a). Bio-informatic and tissue distribution analysis
have been used to identify cognate and surrogate ligands. The orphan receptor gene MrgX2 is a member of the Mrg gene
family that is related to theMas1oncogene (Robas et al., 2003, Allia et al., 2005, Kamohara et al., 2005, Akuzawa et al., 2009,
Kashem et al., 2011, Subramanian et al., 2011a).
The Mrg gene family has been found to undergo strong Darwinian positive selection in mammalian species (Choi and
Lahn, 2003, Tominaga et al., 2003, Tominaga et al., 2005, Zhang et al., 2005, Burstein et al., 2006). Thus, its role in the
adaptive evolution of the pain-perception-related nervous system and immune system functions could be focused in future.
Nevertheless, their detailed functions and the relative mechanisms of signal transduction are still not well understood (Choi
and Lahn, 2003, Zhang et al., 2005, Burstein et al., 2006).
Study onMrgs is a new research ﬁeld and will help researchers to understand pain mechanisms, nociceptor development
and immunesystemfunctions. Itmayalso contribute tonewtargeteddrugsdevelopment.Asanewlyevolved familymember,
human MrgX2 may play a role in the evolution of the human nervous system and is very important to mast cells. The aim of
this article was to review the recent progress in research on the gene MrgX2, including its origin, expression, functions and
future research foci.
2. The location, evolution and future research focus of MrgX2
2.1. The location of MrgX2
HumanMrgX2gene is a two-exon gene located on chromosome 11p15 and encoding a protein with 330 amino acids.
Data on MrgX2 chromosomal location in other primates were shown in Table 1. With the completion of the human genome
project, hundreds of orphan GPCRs have been reported (Choi and Lahn, 2003).2.2. Rapid evolution of Human MrgX2 (hMrgX2)
It has been reported that all humanMrgXgenes are closely related to each other and this result is from recent gene dupli-
cations that postdate primate-rodent divergence (Burstein et al., 2006). Yang et al. (Yang et al., 2005) sequenced theMrgX2
Table 1
Chromosomal Location of MrgX2 in Primates.
Species Location Exons Coding exons Transcript length Translation length
Human
(Homo sapiens)
chromosome 11 2 1 2,036 bps 330 residues
Chimpanzee
(Pan troglodytes)
chromosome 11 2 1 — 330 residues
Orangutan
(Pongo abelii)
chromosome 11 1 1 993 bps 330 residues
Gibbon
(Nomascus leucogenys)
Supercontig GL397264 2 2 2,035 bps 358 residues
Macaque
(Macaca mulatta)
chromosome 14 2 1 2,033 bps 329 residues
Marmoset
(Callithrix jacchus)
chromosome 11 3 1 2,047 bps 330 residues
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Table 2
Expression analysis of MrgX2.
Detection Main location Expression
Level
Reference
MrgX2 DRGs +++++ Robas et al.,
2003
Testis, small intestine, spinal cord, pancreas, lung, heart, thymus, and colon +++
Cord blood-derived mast cells, compound 48/80 activates transfected cells +++ Tatemoto et al.,
2006,
Subramanian
et al., 2011b
MrgX2 Small neurons in DRG (highest), TRG and cerebral cortex +++++ Robas et al.,
2003
Moderate neurons in DRG (highest), TRG and cerebral cortex +++
Testis spermatocytic precursors ++
Small intestine endothelium and vascular smooth muscle +
Hippocampus CA2, CA3 and CA4 +
Hippocampus CA1 n.d.
Neurohypophysis, blood vessels +++ Allia et al., 2005
Skin mast cells, cord blood-derived mast cells, CD34+ cell-derived mast cells, a human mast
cell line LAD2
+++ Tatemoto et al.,
2006, Kajiwara
et al., 2010,
Subramanian
et al., 2011b
Lymph nodes, spleen, or peripheral blood leukocytes n.d. Tatemoto et al.,
2006
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ene in world-wide human populations and primate species. Their studies on DNA polymorphism patterns showed an
xcess of derived substitutions, implying the occurrence of adaptive evolution ofMrgX2 in human (Yang et al., 2005). Three
f the four human-speciﬁc amino acid substitutions were located extra-cellularly, which is important for the interaction
ith ligands, potentially leading to adaptive changes in the pain-perception-related nervous system or mast cell migration
ctivities during human evolution (Yang et al., 2005). All these results demonstrated a strong Darwinian positive selection
n humans, which may contribute to adaptive changes of the sensory system or immune system during human evolution
Yang et al., 2005, Zhang et al., 2005).
.3. Future research focus of MrgX2
It is still unclear why rapid mutation of MrgX2 occurred in human and what this rapid evolution implies. An evolutionary
unctional analysis of the mutants probably need to be performed to understand the Darwinian rapid evolution of MrgX2.
rgX2 ancient sequences in primates can be obtained by the ancient sequence reconstruction method. Cell lines such as
EK293 can be used to determine the different mutation types of human MrgX2. The ancestor mutant genes along primate
volution help to understand the role of MrgX2 in the defense against microorganisms and pain modulation of sensory
eurons. The calcium mobilization, degranulation and chemotaxis assays maybe help to understand the mutant meaning of
he gene in the human beings. The evolutionary meaning of the mutations in human and other primates might help us to
nderstand MrgX2 and even the Mrg gene family. In addition, the functional evolutionary analysis and mechanism of pain
odulation of MRG proteins, as well as its functions in mast cells, would be important to understand the evolution of the
rimate and even mammalian nervous system and immune system. This would also be helpful for the development of drugs
o alleviate pain, combat cancer and microbial infections. In our opinion, the immune driving force could cause mutations
nd lead to speciﬁc anti-microbial actions or immune activity adjustments. In this regard, MrgX2 signaling and regulation
n mast cells might become a future research focus.
. The expression pattern of MrgX2
Asubgroupof receptors (MRGX1–MRGX4) is expressed inhumanbutnotmurineneurons. Immuno-histochemical studies
ave been carried out in various normal and diseased human tissues and the results were summarized in Table 2. MRGX2
as a limited expression proﬁle in both the peripheral and central nervous system, being most abundant in DRGs and TRGs
Robas et al., 2003). Quantitative polymerase chain reaction (PCR) data has conﬁrmed that the highest levels of MrgX2 were
bserved in lumbar DRGs but high transcript levels were also seen in DRGs isolated from thoracic and cervical regions. These
eceptors were speciﬁcally found in the small-sized sensory neurons of DRGs and TRGs that are thought to be involved in
he sensation and modulation of pain.
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Table 3
Immuno-modulatory activities of peptides that have been demonstrated in vivo.
Peptide Activity Associated G
protein type
References
PAMP-12 & PAMP-20 Adrenal chromafﬁn regulates catecholamine secretion
from adrenal glands
Gi/o Belloni et al.,
1999;
Kamohara
et al., 2005
PAMP Elicit hypotension through inhibiting catecholamine
secretion from sympathetic nerve endings and adrenal
chromafﬁn cells
Gi Kamohara
et al., 2005
CST; CST-14 & CST-17 Induction of slow wave sleep, inhibition of locomotor
activity, and inhibit- ion of cell proliferation
Gq Robas et al.,
2003
-defensins Stimulate degranulation in rat peritoneal mast cells
in vitro and cause increased vascular permeability in
rats in vivo
Gq & Gi Takano and
Fujita, 1999
Dextrorphan and 3-methoxy morphanin Function unknown, pain related G Takeda et al.,
2003; Hinson
et al., 1998
LL-37 S. aureus, E. coli sepsis, anti-endotoxin, wound healing,
adjuvant, angiogenesis
Gáq Lau et al., 2005;
Subramanian,
Kashem et al.,
2011Analysis of MRGX2 expression by immunohistochemistry in prostate samples revealed prominent staining of MRGX2
in the glandular epithelium whereas the ﬁbromuscular stroma stained only faintly (Aicher et al., 2009). In contrast, tissues
frombenign prostatic hyperplasia exhibited only a slight increase in staining in the glandular epitheliumbut very prominent
staining in the ﬁbromuscular stroma (Choi and Lahn, 2003).
MRGX2 was also expressed in human mast cells, including skin mast cells, cord blood-derived mast cells, CD34+ cell-
derived mast cells, compound 48/80 activated transfected mast cells and a mast cell line LAD2 (Subramanian et al.,
Subramanian et al., Tatemoto et al., 2006, Okayama et al., 2008, Niyonsaba et al., 2010, Kashem et al., 2011, Subramanian
et al., 2013). Interestingly, this receptor is only present in mast cells, but not other 41 human cell types examined, e.g.
lymph nodes, spleen, peripheral blood leukocytes, etc. In addition, LAD2 and CD34+ cell-derived primary human mast cells
express functional MRGX1 and MRGX2, but the immature human mast cell line HMC-1 does not (Subramanian et al., 2011a,
Subramanian et al., 2011b, Subramanian et al., 2013). Rat basophilic leukemia cell line RBL-2H3 and murine BMMCs do not
express MRGX2 either. However, it may prove challenging to use an animal model to deﬁne the physiological effects of
MRGX2 activation since studies have shown no mouse or rat orthologues of MrgX2.
The speciﬁc expression pattern of MrgX2 in mast cells suggests its importance in inducing degranulation or other impor-
tant functions. Microarray expression data of primates, especially that of human, are appearing rapidly in the literature. The
difference in expression of MrgX2 between patients with speciﬁc immune diseases and normal people may be analyzed by
data mining.
4. Interaction of MRGX2 with peptide factors
Peptides known to activate human MRGX2 can be activated in the corresponding rhesus ortholog using GTP-gS-binding
assays. The results were sumarized in Table 3.
4.1. Substance P and vasoactive intestinal peptide activate MRGX2
SubstancePandvasoactive intestinal peptide couldactivateMRGX2 (Zhanget al., 2005). In the caseofmacaqueMRGX2, its
expression was co-localized with the known nociceptive neuronal markers IB4, VR1, Substance P and vasoactive intestinal
peptide (Zhang et al., 2005), suggesting that MRGX2 is involved in the modulation of nociception and contributes to the
late-phase reaction of allergy.
With regard to allergy reaction, Fujisawa et al. (Fujisawa et al., 2014) found that it was signiﬁcantly more intense and
long-lasting in patients with chronic urticaria, and their mast cells expressed more MRGX2 than that of normal people.
The percentage of MRGX2-positive skin mast cells and MRGX2-positive mast cells in patients with chronic urticaria were
signiﬁcantly greater than those in non-chronic urticaria subjects. Thus, MRGX2 may be the receptor of mast cells that
contributes to the late-phase reaction of allergy.
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.2. Cortistatin (CST), proadrenomedullin N-terminal peptide (PAMP), Dextrorphan and 3-methoxy morphanin activate
RGX2
In human, CST is a cyclic peptide derived from a pre-propeptide of 114 residues and has been shown to play a role in
he induction of slow wave sleep and inhibition of locomotor activity and cell proliferation (Rubinfeld and Shimon, 2006,
roglio et al., 2007, Broglio et al., 2008, Gahete et al., 2008, Siehler et al., 2008, Van Hagen et al., 2008, Volante et al., 2008,
aranowska et al., 2009). Small molecules, peptides and bioactive lipids, e.g. CST-14 and -17, contain both the N-terminal
roline and the C-terminal lysine amide, exhibit high afﬁnity for MRGX2, and may activate GPCR. Overlapping distribution
f MRGX2 and CST was seen in DRGs, testis and pancreas (Allia et al., 2005).
Recently, PAMP (Kamohara et al., 2005), especially the PAMP-12, were identiﬁed as endogenous ligands for MRGX2.
igands of MRGX2 have been screened using an MRGX2-Gi fusion protein expressed by Sf 9 cells (Subramanian et al.,
011a), demonstrating that MRGX2 is a Gi/o protein-coupled receptor activated by PAMP.
Dextrorphan and3-methoxymorphanin,which aremorphine analogs, are also found to partially activateMRGX2 (Tanaka
t al., 2003). MRGX2-expressing cells were stimulated not only by CST and PAMP, but also by morphine and its derivatives
xcluding leucine-enkephalin and -endorphin (Subramanian et al., 2011a, Subramanian et al., 2011b, Subramanian et al.,
013).
.3. LL-37 activates MRGX2
LL-37belongs to a groupof antimicrobial peptide gene family cathelicidins,with somemembers havingpleiotropic effects
n addition to their antibacterial, antifungal and antiviral activities. They also exhibit chemotactic and immuno modulatory
unctions (Niyonsaba et al., 2001, Niyonsaba et al., 2003). Furthermore, they are involved in wound healing, angiogenesis
nd apoptotic pathway. Recent analysis indicated that they also participate in cancer (Niyonsaba et al., 2010). MRGX2 is a
olecular target of LL-37. Through various inﬂammatory signaling pathways, MRGX2 could be activated or modulated by
L-37, resulting in inﬂammatory responses by activating cytoplasmic targets to release cytokines, control cell motility, and
ause cell proliferation (Subramanian et al., 2011a, Vandamme et al., 2012, Lee et al., 2013).
LL-37 interacts with the Gi protein-coupled receptor MRGX2 on mast cells. Furthermore, the experimental results from
nockdown of MrgX2 in human mast cells has shown that LL-37 induces sustained Ca2+ mobilization and degranulation
ia MRGX2. Moreover, LL-37 promotes chemotaxis and induces chemokine CCL4 via MRGX2 in transfected mast cell lines
Subramanian et al., 2011a).
Although MRGX2 has been identiﬁed as a key receptor of LL-37 on mast cells, other unidentiﬁed GPCRs have also been
roposed as receptors for LL-37 (Lau et al., 2005, Lau et al., 2006) and implicated in LL-37-mediated modulation of DC
ifferentiation. Based on inhibition of LL-37-mediated effects by pertussis toxin, Davidson (Davidson et al., 2004) showed
hat LL-37 could cause chemotaxis, degranulation and chemokine production in human mast cells, but it could not induce
eceptor desensitization.
.4. PMX-53 may activates human mast cells via MRGX2
It is currently unknown whether this receptor is activated by endogenous peptides produced in the context of innate
mmunity and inﬂammation. However, human defensins, which are amphiphilic peptides, induce mast cell degranulation
t concentrations similar to those observed for PMX-53 (Subramanian et al., 2011b). Defensins produced by epithelial cells
uring microbial infection may activate human mast cells via MRGX2 to promote innate immunity. It is possible, therefore,
hat the dual effect of PMX-53 could be pharmacologically relevant in promoting both anti-inﬂammatory activity and innate
mmunity. Thus, at low concentrations, PMX-53 could block inﬂammation by acting as a CD88 antagonist, but it can promote
nnate immunity at higher concentrations, throughmimicking the actions of defensins onmast cell activation (Subramanian
t al., 2011a, Subramanian et al., 2011b, Subramanian et al., 2013).
.5. ˇ-defensins activate human mast cells via MRGX2
Human -defensins can activate human mast cells via MRGX2. Both PT-sensitive and insensitive signaling pathways
ost likely involving Gq and Gi are involved in the degranulation of mast cells. In contrast, murine mast cells are resistant
o -defensins for degranulation, and this reﬂects the absence of MRGX2 in these cells. In addition, silencing the expression
f MRGX2 in human mast cells could inhibit -defensin-induced degranulation, but could not inﬂunecne the anaphylatoxin
3a-induced response. Furthermore, ectopic expression of MRGX2 in RBL-2H3 and murine BMMCs rendered these cells
esponsive to -defensins for degranulation (Niyonsaba et al., 2003, Chen et al., 2007, Niyonsaba et al., 2010, Subramanian
t al., 2013).. The function of MRGX2 and further research clue
Recently, MRGX receptors have been found in the macaque (Zhang et al., 2005). As rhesus monkey is a commonly
sed animal model for experimental biology and drug discovery, Zhang (Zhang et al., 2005) cloned and pharmacologically
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analyzed rhesus monkey MRGX receptor counterparts for each of the known human MRGX receptors, and found that they
are functionally as well as structurally similar to the known human MRGX receptors. These data suggest that the rhesus
monkey may be a suitable animal model for exploring the physiological roles of MRGX receptors. Most of the human and
rhesus MRGX receptor subtypes displayed high constitutive activity in a cellular proliferation assay.
To investigate the downstream signaling of MRGX2, the increase or decrease of intracellular cAMP was monitored in
response to MRGX2 activation. In MRGX2-expressing cells, CST stimulated an increase in intracellular Ca2+ but did not show
inﬂuence on cAMP levels. These results taken together indicate that this receptor functions via a Gq associated mechanism.
The identiﬁcation of MRGX2 as the ﬁrst human CST-preferred receptor, together with the colocalization of the receptor and
ligand in the DRG, should promote investigation into the role of CST and its receptor in nociception.MRGA1,MRGA4,MRGX1
and a rat MRG receptor, all of which share 45–65% amino acid identity with MRGX2, exhibit overlapping expression within
small diameter ﬁbers of the DRG neurons. The structure-activity relationships and rank order of potency of their respec-
tive ligands are distinct, suggesting the involvement of the Mrg family in subtle regulation and ﬁne-tuning of nociceptive
responses.
Cortistatin-14 (CST-14) is a high afﬁnity ligand for the orphan receptor MRGX2 and has been shown to play a role in the
induction of slow wave sleep, inhibition of locomotor activity and cell proliferation. Immuno-histochemical studies show
moderate levels ofMRGX2 expression in subsets of neurons in the CA2, CA3, and CA4 regions of the hippocampus, suggesting
that it is highly related with CST. Quantitative PCR studies show CST to have a broad tissue distribution as compared with
the limited expression of MrgX2. This is not unexpected as a number of the diverse actions of CST have been shown to be
mediated via interactions with the widely distributed somatostatin family of receptors.
Humanmast cell line LAD2andCD34+ cell-derivedprimarymast cells canexpressMRGX2, responded to LL-37, andﬁnally
resuled in Ca2+ mobilization and degranulation. In contrast, an immature human mast cell line HMC-1 that lacks functional
MRGX2 did not respond to LL-37. After MrgX2 is knocked down, LAD2 mast cell line and primary CD34+ cell-derived mast
cells show a decrease in the LL-37-induced degranulation. Furthermore, mast cell lines stably expressing MRGX2 responded
to LL-37 for chemotaxis, degranulation, and CCL4 production. Nevertheless, MRGX2 was resistant to the phosphorylation,
desensitization, and internalization induced by LL-37. In addition, knockdown of the GPCR kinases (GRK2 and GRK3) had no
effect on LL-37-induced mast cell degranulation. This study identiﬁed MRGX2 as a novel GPCR for the antibacterial peptide
LL-37, andunlikemostGPCR, it is resistant to agonist-induced receptor phosphorylation, desensitization, and internalization.
6. Conclusions
MrgX2 has undergone adaptive changes along the human evolution, and this was probably caused by Darwinian positive
selection. In addition,MrgX2 along with Mrg gene family has undergone strong Darwinian positive selection in mammalian
species, therefore, an implication of its involvement in the adaptive evolution of the pain-perception-related nervous system
and immune system.
Bio-informatics and tissuedistributionanalysis canbeused toprioritize thoseorphan receptorswithpotential therapeutic
relevance. A “reverse pharmacology” method can be used to identify cognate and surrogate ligands. MrgX2 is gene that is
primarily expressed in human DRGs, TRGs and mast cells.MRGX2 can interact with various peptides, including substance
P, vasoactive intestinal peptide, CST, PAMP, LL-37, PMX-53, and -defensins for multiple functions such as nociception and
immune defense. However, the detailed physiological functions of theMRGX2 receptors and the underlying mechanisms of
signal transduction still need to be explored.
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